J Vardy1, H M Dhillon2, G R Pond3, S B Rourke4, W Xu5, A Dodd5, C Renton2, A Park5, T Bekele6, J Ringash5, H Zhang7, R Burkes8, S J Clarke2, I F Tannock5. 1. Sydney Medical School, University of Sydney, Sydney, Australia; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada; Concord Cancer Centre, Concord Hospital, Concord, Australia. Electronic address: janette.vardy@sydney.edu.au. 2. Sydney Medical School, University of Sydney, Sydney, Australia. 3. Department of Oncology, McMaster University, Hamilton. 4. St Michael's Hospital, University of Toronto, Toronto; The Ontario HIV Treatment Network, Toronto. 5. Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. 6. The Ontario HIV Treatment Network, Toronto. 7. Keenan Research Centre for Biomedical Research, St Michael's Hospital, University of Toronto, Toronto. 8. Mt Sinai Hospital, University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: Cognitive impairment and fatigue have been associated with cancer and its treatment. We present baseline data from a large longitudinal study that evaluates cognitive function, fatigue, and potential underlying mechanisms following diagnosis of colorectal cancer (CRC). PATIENTS AND METHODS: We evaluated CRC patients with stage I-III disease before or after surgery, participants with limited metastatic disease and healthy controls (HC). Neuropsychological evaluation included clinical and computerised tests. Participants completed questionnaires for fatigue and quality of life (QOL)-(FACT-F), anxiety/depression, and cognitive symptoms (FACT-Cog). Ten cytokines, clotting factors, sex hormones, carcinoembryonic antigen (CEA), and apolipoprotein E genotype were evaluated. Primary end points were cognitive function on clinical tests evaluated by a Global Deficit score (GDS) and fatigue. Associations between test results, demographic, and disease related factors were explored. RESULTS: We assessed 291 participants with early-stage disease [median age 59 (23-75) years, 63% men], 72 with metastatic disease, and 72 HC. Using GDS, 45% (126/281) of participants with early-stage CRC had cognitive impairment versus 15% (11/72) of HC (odds ratio 4.51, 95% confidence interval 2.28-8.93; P < 0.001), with complex processing speed, attention/working memory, and verbal learning efficiency being most affected. Women with early-stage CRC had greater cognitive impairment than men [55/105 (52%) versus 71/176 (40%), P < 0.050]. Cognitive symptoms were self-reported by 21% (59/286) of early-stage patients versus 17% (12/72) of HC; fatigue by 52% (149/287) of early-stage patients and 26% (19/72) of HC (P < 0.0001). Women reported more fatigue than men (P = 0.003). Fatigue, QOL, anxiety/depression, and cognitive symptoms were associated with each other (r = 0.43-0.71), but not with neuropsychological performance. Most cytokines were elevated in cancer patients. Cognitive function was not associated with cytokines, sex hormones, clotting factors, CEA, or apolipoprotein E genotype. CONCLUSIONS: The incidence of cognitive impairment was three to five times higher in CRC patients than HC, with women having higher impairment rates than men. The cognitive impairment profile suggests dysfunction primarily in fronto-subcortical brain systems. TRIAL REGISTRATION: NCT00188331.
BACKGROUND:Cognitive impairment and fatigue have been associated with cancer and its treatment. We present baseline data from a large longitudinal study that evaluates cognitive function, fatigue, and potential underlying mechanisms following diagnosis of colorectal cancer (CRC). PATIENTS AND METHODS: We evaluated CRC patients with stage I-III disease before or after surgery, participants with limited metastatic disease and healthy controls (HC). Neuropsychological evaluation included clinical and computerised tests. Participants completed questionnaires for fatigue and quality of life (QOL)-(FACT-F), anxiety/depression, and cognitive symptoms (FACT-Cog). Ten cytokines, clotting factors, sex hormones, carcinoembryonic antigen (CEA), and apolipoprotein E genotype were evaluated. Primary end points were cognitive function on clinical tests evaluated by a Global Deficit score (GDS) and fatigue. Associations between test results, demographic, and disease related factors were explored. RESULTS: We assessed 291 participants with early-stage disease [median age 59 (23-75) years, 63% men], 72 with metastatic disease, and 72 HC. Using GDS, 45% (126/281) of participants with early-stage CRC had cognitive impairment versus 15% (11/72) of HC (odds ratio 4.51, 95% confidence interval 2.28-8.93; P < 0.001), with complex processing speed, attention/working memory, and verbal learning efficiency being most affected. Women with early-stage CRC had greater cognitive impairment than men [55/105 (52%) versus 71/176 (40%), P < 0.050]. Cognitive symptoms were self-reported by 21% (59/286) of early-stage patients versus 17% (12/72) of HC; fatigue by 52% (149/287) of early-stage patients and 26% (19/72) of HC (P < 0.0001). Women reported more fatigue than men (P = 0.003). Fatigue, QOL, anxiety/depression, and cognitive symptoms were associated with each other (r = 0.43-0.71), but not with neuropsychological performance. Most cytokines were elevated in cancerpatients. Cognitive function was not associated with cytokines, sex hormones, clotting factors, CEA, or apolipoprotein E genotype. CONCLUSIONS: The incidence of cognitive impairment was three to five times higher in CRC patients than HC, with women having higher impairment rates than men. The cognitive impairment profile suggests dysfunction primarily in fronto-subcortical brain systems. TRIAL REGISTRATION: NCT00188331.
Authors: Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2004-05 Impact factor: 2.475
Authors: T W Robbins; M James; A M Owen; B J Sahakian; A D Lawrence; L McInnes; P M Rabbitt Journal: J Int Neuropsychol Soc Date: 1998-09 Impact factor: 2.892
Authors: Marc A Norman; David J Moore; Michael Taylor; Donald Franklin; Lucette Cysique; Chris Ake; Deborah Lazarretto; Florin Vaida; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2011-06-24 Impact factor: 2.475
Authors: Patricia A Ganz; J E Bower; L Kwan; S A Castellon; D H S Silverman; C Geist; E C Breen; M R Irwin; S W Cole Journal: Brain Behav Immun Date: 2012-08-03 Impact factor: 7.217
Authors: Tim A Ahles; Andrew J Saykin; Walter W Noll; Charlotte T Furstenberg; Stephen Guerin; Bernard Cole; Leila A Mott Journal: Psychooncology Date: 2003-09 Impact factor: 3.894
Authors: Nadine Tchen; Helen G Juffs; Fiona P Downie; Qi-Long Yi; Hanxian Hu; Irene Chemerynsky; Mark Clemons; Michael Crump; Paul E Goss; David Warr; Mary E Tweedale; Ian F Tannock Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Unni Dokkedal; Tom G Hansen; Lars S Rasmussen; Jonas Mengel-From; Kaare Christensen Journal: Anesthesiology Date: 2016-02 Impact factor: 7.892
Authors: Mackenzi Pergolotti; Nicolò Matteo Luca Battisti; Lynne Padgett; Alix G Sleight; Maya Abdallah; Robin Newman; Kathleen Van Dyk; Kelley R Covington; Grant R Williams; Frederiek van den Bos; YaoYao Pollock; Elizabeth A Salerno; Allison Magnuson; Isabella F Gattás-Vernaglia; Tim A Ahles Journal: J Geriatr Oncol Date: 2019-10-14 Impact factor: 3.599
Authors: Haryana M Dhillon; Ian F Tannock; Gregory R Pond; Corrinne Renton; Sean B Rourke; Janette L Vardy Journal: J Cancer Surviv Date: 2017-10-27 Impact factor: 4.442
Authors: Erik Boberg; Nadir Kadri; Jeanette Winterling; Lindsay C Davies; Andreas Björklund; Mussie Msghina; Ellen Iacobaeus; Katarina Le Blanc Journal: Haematologica Date: 2019-10-24 Impact factor: 9.941
Authors: Michael Renner; Rebekah Feng; Danielle Springer; Mei-Kuang Chen; Andre Ntamack; Alexandra Espina; Leorey N Saligan Journal: Behav Brain Res Date: 2016-03-21 Impact factor: 3.332
Authors: J L Vardy; H M Dhillon; G R Pond; C Renton; A Dodd; H Zhang; S J Clarke; I F Tannock Journal: Ann Oncol Date: 2016-07-20 Impact factor: 32.976